A Phase Ia, Randomized, Placebo-Controlled, Single-Dose, Double-Blind, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of SQ109 in Normal, Healthy Male and Female Volunteers

Sequella, Inc.1 个研究点分布在 1 个国家目标入组 62 人开始时间: 2006年9月最近更新: 2013年8月19日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Sequella, Inc.
入组人数: 62
试验地点: 1
主要终点: Safety

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This is a phase 1, "first in man" study to evaluate single oral doses (5-300 mg) of SQ109, a new investigational drug being developed for treatment of tuberculosis. If single doses are safe and well tolerated, subsequent studies will evaluate multiple daily doses in healthy volunteers and patients with pulmonary tuberculosis.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Single Group
主要目的: Treatment
盲法: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围: 18 Years 至 55 Years（Adult）
性别: Male
接受健康志愿者: 是

入选标准

•Subject must be 18 to 55 years of age.
•Subject must be a healthy male or female volunteer (i.e., hematology, coagulation,clinical chemistries and urinalysis tests must be within normal, allowable limits).
•Clinical laboratory tests must be performed within 21 days of receiving first dose of study drug.
•Body weight must be ± 20% of the ideal for height and estimated frame based on the 1983 Metropolitan Life Insurance Company table.
•Subject must give voluntary written informed consent before any study related procedure is performed.
•Female subjects will be postmenopausal, surgically sterile, or agree to use two forms of contraception from screening through 30 days after the dose of study drug. All female subjects of childbearing potential must have a negative urine pregnancy test at screening.
•Male subjects must agree to use an acceptable barrier method for birth control from screening through 30 days after the dose of study drug.

排除标准

•A history of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
•Subject has been on an abnormal diet during the 4 weeks preceding the study. Abnormal diet is defined as a diet in which the subject has a significant change in eating habits (e.g., liquid diet only) and an unbalanced diet (e.g., protein only, high fat, low carbohydrate, etc.).
•Subject has donated blood within 30 days or plasma within 14 days of study dosing.
•Subject has participated in any clinical trial within 30 days prior to study initiation; herein, 30 days are defined as 30 days from the last dosing in a clinical trial
•Subject has used any over-the-counter (OTC) medication, including vitamins, within 7 days prior to the study.
•Subject has used any prescription medication within 14 days prior to the study.
•Subject has been treated with any known CYP450 enzyme altering drugs such as azoles, antifungals, barbiturates, phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to the study.
•Subject has a positive blood screen for HIV, hepatitis B surface antigen (HBsAg), or hepatitis C antibody and/or a positive urine screen for alcohol or drugs of abuse.
•Subject has smoked or used tobacco products within 2 months prior to or during the study.
•Subject has an uncontrolled intercurrent illness (i.e., active infection).
•Subject has had major surgery within 4 weeks of study entry.
•Subject has another serious medical or psychiatric illness that could, in the Investigator's opinion, interfere with the completion of treatment according to this protocol.
•Subjects who are color-blind.
•Subjects with QTc interval prolongation (> 450 msec) or a history of QTc interval prolongation.
•Subjects with a history of alcohol abuse, drug and/or food allergies.
•Subjects who intend to consume grapefruit juice during the study.